How can a complete blood count reveal that a patient is on hydroxyurea therapy?

CBC Findings Suggesting Hydroxyurea Therapy

The most characteristic CBC finding indicating hydroxyurea use is macrocytosis (elevated MCV), which is self-limiting and typically appears early in treatment 1.

Key Hematologic Markers on CBC

Primary Indicators

Macrocytosis (Increased MCV) is the hallmark finding:

• Appears early in hydroxyurea therapy 1
• Self-limiting and dose-related
• The morphologic change resembles pernicious anemia but is NOT related to vitamin B12 or folic acid deficiency 1
• Can mask the diagnosis of true pernicious anemia 1
• Detectable HU levels correlate with increased MCV (p < 0.001) 2

Secondary Indicators

White Blood Cell Changes:

• Decreased total WBC count is expected 3
• Mean decrease of 6.17×10³/µL from baseline (p<0.001) 3
• Decreased neutrophils, lymphocytes, monocytes, and basophils 3
• In polycythemia vera: target WBC count ≤10×10⁹/L indicates adequate response 4, 5

Red Blood Cell Parameters:

• Increased hemoglobin content in both RBCs and reticulocytes 6
• Mean hemoglobin increase of 0.77 g/dL (p<0.001) in sickle cell disease 3
• Increased mean corpuscular hemoglobin (MCH) 6, 7
• Changes detectable as early as 10 weeks after starting therapy 6

Platelet Changes:

• In polycythemia vera/essential thrombocythemia: target platelet count ≤400×10⁹/L indicates response 4, 5
• Cyclic platelet oscillations can occur in some patients with polycythemia vera 8

Clinical Context Matters

In Myeloproliferative Neoplasms

Complete response criteria 4, 5:

• Hematocrit <45% without phlebotomy
• Platelet count ≤400×10⁹/L
• WBC count ≤10×10⁹/L
• No disease-related symptoms

In Sickle Cell Disease

Response indicators 3, 6:

• Increased hemoglobin (mean 0.77 g/dL increase)
• Elevated MCV and MCH
• Decreased WBC count
• Changes more pronounced with good adherence

Important Caveats

Myelosuppression as a toxicity marker 1:

• Absolute neutrophil count <1.0×10⁹/L suggests excessive dosing
• Platelet count <100×10⁹/L (or <50×10⁹/L in myelofibrosis) indicates intolerance 4, 9
• Hemoglobin <10 g/dL at lowest effective dose defines intolerance 4, 5

Absence of expected changes suggests:

• Poor adherence (especially in children where only 24% had detectable HU levels) 2
• Suboptimal dosing
• Need for dose adjustment or adherence counseling

Laboratory interference: Hydroxyurea can falsely elevate uric acid, urea, and lactic acid assays 1.

The combination of macrocytosis with controlled myeloproliferation (normalized or decreased WBC and platelet counts in the appropriate clinical context) strongly suggests active hydroxyurea therapy.